N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-isopropoxy-2-oxo-1,2-dihydropyridine-3-carboxamide | 2412309-60-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-isopropoxy-2-oxo-1,2-dihydropyridine-3-carboxamide
• 英文别名: Trk-IN-25；N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxo-6-propan-2-yloxypyridine-3-carboxamide
• CAS: 2412309-60-3
• 化学式: C₃₂H₂₆F₂N₆O₄
• 分子量: 596.593
• InChiKey: XSDZOIYDMHIIAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  44
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• TRK INHIBITOR AS ANTI-CANCER DRUG
  申请人：Tyligand Bioscience (Shanghai) Limited

  公开号：EP3848365A1

  公开（公告）日：2021-07-14

  The present disclosure relates to a group of tropomyosin receptor kinase inhibitors comprising an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.

  本公开涉及一组肌球蛋白受体激酶抑制剂，包括氨基苯氧基吲唑结构片段。这些化合物对各种致癌激酶（尤其是 TRK）具有强效抑制作用，因此可用于治疗肿瘤或癌症。
• TRK INHIBITORS USEFUL AS ANTICANCER DRUGS
  申请人：TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED

  公开号：US20220388983A1

  公开（公告）日：2022-12-08

  A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.